References
- diMasiJAHansenRWGrabowkiHGThe price of innovation: new estimates of drug development costsJ Health Econ20032215118512606142
- PoutonCWFormulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification systemEur J Pharm Sci20062927828716815001
- AnsariMJKohliKDixitNMicroemulsions as potential drug delivery systems: a reviewPDA J Pharm Sci Technol200862667918402369
- DuncanRThe dawning era of polymer therapeuticsNat Rev Drug Discov2003234736012750738
- HaagRKratzFPolymer therapeutics: concept and applicationsAngew Chem Int Ed Engl2006451198121516444775
- LiCYuD-YNewmanRAComplete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)- paclitaxel conjugateCancer Res199858240424099622081
- JainRKTransport of molecules in the tumor interstitium: a reviewCancer Res198747303930513555767
- RingsdorfHStructure and properties of pharmacologically active polymersJ Polym Sci Polymer Symp197551135153
- KimSCKimDWShimYHIn vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacyJ Control Release20017219120211389998
- KimT-YKimD-WChungJ-YPhase I and pharmacokinetic study of genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignanciesClin Cancer Res2004103708371615173077
- HamaguchiTMatsumuraYSuzukiMNK105, paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumor activity and reduce the neurotoxicity of paclitaxelBr J Cancer2005921240124615785749
- NegishiTKoizumiFUchinoHNK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to fee paclitaxelBr J Cancer20069560160616909136
- NakanishiTFukushimaSOkamotoKDevelopment of the polymer micelle carrier system for doxorubicinJ Control Release20017429530211489509
- MatsumuraYHamaguchiTUraTPhase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicinBr J Cancer2004911775178115477860
- NishiyamaNKataokaKPreparation and characterization of size- controlled polymeric micelle containing cis-dichlorodiammineplatinum(II) in the coreJ Control Release200174839411489486
- NishiyamaNOkazakiSCbralHNovel cisplatin-incorporated polymeric micelles can eradicate solid tumors in miceCancer Res2003638977898314695216
- UchinoHMatsumuraYNegishiTCisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in ratsBr J Cancer20059367878716222314
- MonksAScudieroDSkehanPFeasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell linesJ Natl Cancer Inst1991837577662041050
- VeroneseMLFlahertyKKramerAPhase I study of the novel taxane CT-2103 in patients with advanced solid tumorsCancer Chemother Pharmacol20055549750115711828
- BoddyVAPlummerREToddRA phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedulesClin Cancer Res2005117834784016278406
- SabbatiniPAghajanianCDizonDPhase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinomaJ Clin Oncol2004224523453115542803
- LangerCJO’ByrneKJSocinskiMAPhase II trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancerJ Thorac Oncol2008362363018520802
- MathewAEMejillanoMRNathJPHimesRHStellaVJSynthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activityJ Med Chem1992351451511346275
- Reference of gel permeation chromatography with multi-angle light scattering detection Available from: http://wyatt.com/
- WaniMCTaylorHLWallMECoggonPMcPhailATPlant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from taxus BrevifoliaJ Am Chem Soc197193232523275553076
- WangXZhaoGvanSPharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenograftsCancer Chemother Pharmacol20106551552619593566
- ZhonglingFZhaoGYuLGoughDHowellSBPreclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs AbraxaneCancer Chemother Pharmacol20106592393019685054